ATE466069T1 - Peptid-konjugierte antikrebs-prodrugs - Google Patents
Peptid-konjugierte antikrebs-prodrugsInfo
- Publication number
- ATE466069T1 ATE466069T1 AT01967657T AT01967657T ATE466069T1 AT E466069 T1 ATE466069 T1 AT E466069T1 AT 01967657 T AT01967657 T AT 01967657T AT 01967657 T AT01967657 T AT 01967657T AT E466069 T1 ATE466069 T1 AT E466069T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- conjugated anti
- cancer
- chemotherapeutic drug
- cancer prodrugs
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22973300P | 2000-09-05 | 2000-09-05 | |
| PCT/IL2001/000839 WO2002020715A2 (en) | 2000-09-05 | 2001-09-05 | Peptide conjugated anti-cancer prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466069T1 true ATE466069T1 (de) | 2010-05-15 |
Family
ID=22862481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01967657T ATE466069T1 (de) | 2000-09-05 | 2001-09-05 | Peptid-konjugierte antikrebs-prodrugs |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7135547B2 (enExample) |
| EP (2) | EP1581615B1 (enExample) |
| AT (1) | ATE466069T1 (enExample) |
| AU (1) | AU2001288025A1 (enExample) |
| DE (1) | DE60141992D1 (enExample) |
| IL (1) | IL154696A (enExample) |
| WO (1) | WO2002020715A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| WO2004093807A2 (en) * | 2003-04-22 | 2004-11-04 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Somatostatin vectors |
| AU2004248138B2 (en) * | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| AT412785B (de) | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| WO2005097089A2 (en) * | 2004-04-02 | 2005-10-20 | Wisconsin Alumni Research Foundation | Derivatives of leinamycin for use as anticancer agents |
| BRPI0617549A2 (pt) * | 2005-09-26 | 2011-07-26 | Medarex Inc | anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo |
| CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
| EP2097534A4 (en) * | 2006-12-14 | 2010-05-12 | Medarex Inc | HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF |
| US20100316697A1 (en) * | 2007-05-10 | 2010-12-16 | Clear Direction Ltd. | Methods and compositions for drug targeting |
| KR101032860B1 (ko) * | 2008-10-22 | 2011-05-06 | 한국식품연구원 | 췌장 조직 특이적 유전자 ｍｍｐ1 |
| CN101747411B (zh) * | 2008-11-28 | 2012-07-25 | 北京大学 | 氨基酰色氨酰色氨酸三肽苄酯及其制备方法和应用 |
| AU2010306899B2 (en) * | 2009-10-13 | 2015-07-23 | The Johns Hopkins University | Biomarker for identification of melanoma tumor cells |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| HRP20150664T1 (hr) * | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| PL394618A1 (pl) * | 2011-04-19 | 2012-10-22 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
| US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
| US9081001B2 (en) | 2012-05-15 | 2015-07-14 | Wellstat Diagnostics, Llc | Diagnostic systems and instruments |
| US9155799B2 (en) | 2012-11-19 | 2015-10-13 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
| US8940684B2 (en) | 2012-11-19 | 2015-01-27 | Mimedx Group, Inc. | Cross-linked collagen comprising an antifungal agent |
| US8946163B2 (en) | 2012-11-19 | 2015-02-03 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
| US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
| US10335433B2 (en) | 2013-04-10 | 2019-07-02 | Mimedx Group, Inc. | NDGA polymers and metal complexes thereof |
| US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
| WO2015031681A1 (en) | 2013-08-30 | 2015-03-05 | Mimedx Group, Inc. | Micronized placental compositions comprising a chelator |
| KR102272213B1 (ko) * | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| CA3007065C (en) | 2015-12-03 | 2023-02-14 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US11939609B2 (en) | 2017-07-24 | 2024-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system |
| CA3086751A1 (en) | 2018-01-08 | 2019-07-11 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| KR102544277B1 (ko) * | 2020-01-15 | 2023-06-16 | 재단법인대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
| US20210402001A1 (en) * | 2020-06-30 | 2021-12-30 | David I. Cohen | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers |
| TW202328170A (zh) * | 2021-09-14 | 2023-07-16 | 美商艾希利歐發展股份有限公司 | 可裂解連接子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983000150A1 (en) * | 1981-07-02 | 1983-01-20 | Walton, Alan, G. | Glycosaminoglycan drug complexes |
| GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| EP0688327B1 (en) * | 1993-03-01 | 1999-05-06 | Glycan Pharmaceuticals, Inc. | Analogs for specific oligosaccharide-protein interactions and uses therefor |
| CA2158745C (en) | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
| US5612474A (en) * | 1994-06-30 | 1997-03-18 | Eli Lilly And Company | Acid labile immunoconjugate intermediates |
| US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| DE19701141C1 (de) * | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| CA2372053C (en) * | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CN101374856A (zh) * | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
-
2001
- 2001-09-05 DE DE60141992T patent/DE60141992D1/de not_active Expired - Lifetime
- 2001-09-05 AU AU2001288025A patent/AU2001288025A1/en not_active Abandoned
- 2001-09-05 EP EP01967657A patent/EP1581615B1/en not_active Expired - Lifetime
- 2001-09-05 AT AT01967657T patent/ATE466069T1/de not_active IP Right Cessation
- 2001-09-05 IL IL154696A patent/IL154696A/en active IP Right Grant
- 2001-09-05 WO PCT/IL2001/000839 patent/WO2002020715A2/en not_active Ceased
- 2001-09-05 EP EP10156533.1A patent/EP2272947B1/en not_active Expired - Lifetime
-
2003
- 2003-03-05 US US10/382,240 patent/US7135547B2/en not_active Expired - Lifetime
-
2006
- 2006-11-02 US US11/555,939 patent/US7638127B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20030216298A1 (en) | 2003-11-20 |
| WO2002020715A3 (en) | 2006-01-12 |
| EP1581615A4 (en) | 2005-10-05 |
| EP1581615B1 (en) | 2010-04-28 |
| AU2001288025A8 (en) | 2006-11-02 |
| AU2001288025A1 (en) | 2002-03-22 |
| US7638127B2 (en) | 2009-12-29 |
| DE60141992D1 (enExample) | 2010-06-10 |
| IL154696A (en) | 2008-11-03 |
| EP2272947A1 (en) | 2011-01-12 |
| US20070160573A1 (en) | 2007-07-12 |
| EP2272947B1 (en) | 2016-08-10 |
| IL154696A0 (en) | 2003-09-17 |
| WO2002020715A2 (en) | 2002-03-14 |
| EP1581615A2 (en) | 2005-10-05 |
| US7135547B2 (en) | 2006-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE466069T1 (de) | Peptid-konjugierte antikrebs-prodrugs | |
| HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
| ATE252601T1 (de) | Lang wirkende insulinotrope peptide | |
| TR200202183T2 (tr) | Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları | |
| WO2001062300A3 (en) | Caspase activated prodrugs therapy | |
| HN2001000243A (es) | Inhibidores de metaloproteinasa del tipo pirimidin - 2, 4, 6 - triona | |
| ATE471161T1 (de) | Konjugierte prodrogen von cc-1065 analoga | |
| PT1178958E (pt) | N-cianometilamidas como inibidores de proteases | |
| DE60122335D1 (de) | Zusammensetzung auf der basis polymerer mizellen | |
| GEP20043200B (en) | Therapeutic Agent Comprising a Botulinum Neurotoxin | |
| WO2002013873A3 (en) | P97-active agent conjugates and their methods of use | |
| AR032293A1 (es) | Estuche farmaceutico | |
| TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
| GR3035593T3 (en) | Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases | |
| Nichifor et al. | Polymeric prodrugs of 5-fluorouracil | |
| DE60117247D1 (de) | Phosphoramidat-prodrugs | |
| WO2001085777A3 (en) | Therapeutic pore-forming peptides | |
| WO2001095945A3 (en) | Prodrug compounds cleavable by thimet oligopeptidase | |
| ATE349221T1 (de) | Extrakt mit antitumoraler und antitoxischer wirkung | |
| ATE371737T1 (de) | Proteaseresistente flint-analoge | |
| DE69635806D1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
| WO2002057246A3 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| NZ533738A (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
| SE0000303D0 (sv) | Novel compounds | |
| ATE301469T1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |